Amgen Inc.

A Fortune 500 company established in 1980, Amgen (Applied Molecular Genetics) pioneered the recombinant DNA and molecular biology products. The company is said to be in the line of biotechnology entrepreneurialism. The company is an advocate of cancer care as well as the treatment of anemia, rheumatoid arthritis and other autoimmune diseases. The company headquarter is located at Thousand Oaks, California.

AMGN is the ticker for Amgen in NASDAQ. Last year the company did not performed that well in the stock market they even restructured and shrink the organization to cushion the impact. Investing in AMGN might still be good considering the performance of the company at the present date. One of the major reasons for the revenue drop last year was their venture on anemia medicine Aranesp used in cancer patients they spent a lot on safety testing of the said medicine. Don't just take my word for it. There are a ton of personal finance blogs out there saying the same things.

Even if Amgen did not performed well in the stock market last year, there are still things that the company can be proud of, for one, they received authorization to produce drugs like Romiplostim and Panitumumab from major countries like the US, European Union, Canada and Australia. This will be a promising development that will pave way to a brighter future for the company. Another highlight for the company is the citation from The Scientist Amgen is one of the best places to work in the industry. So its not really that bad at all, the company is still has a future ahead. The company is also good in the aspect of finance. Will it be a good time to buy, sell or hold? Well holding on might be a good option for now but then again you can do further research and maybe use some of the stock trading software or stock market software out there, who knows they might tell a different story. Investing in the company might be a good option right now.